Table 1.
Summary of study characteristics
| Study characteristics | N = 108 n (%) |
|---|---|
| Year | |
| 2002–2005 | 7 (6%) |
| 2006–2010 | 11 (10%) |
| 2011–2015 | 39 (36%) |
| 2016–2021 | 51 (47%) |
| Continent | |
| North America | 51 (47%) |
| Europe | 26 (24%) |
| Asia | 28 (26%) |
| Australia | 3 (3%) |
| Gene | |
| CYP2B6 | 2 (2%) |
| CYP2C19 | 25 (23%) |
| CYP2C9 | 1 (1%) |
| CYP2D6 | 6 (6%) |
| DPYD | 5 (5%) |
| HLA‐A*31:01 | 1 (1%) |
| HLA‐B*15:02 | 7 (6%) |
| HLA‐B*57:01 | 8 (7%) |
| HLA‐B*58:01 | 10 (9%) |
| IFNL3 (IL‐28B) | 2 (2%) |
| mt‐RNR1 | 1 (1%) |
| TPMT | 11 (10%) |
| UGT1A1 | 1 (1%) |
| Multiple genes | 28 (26%) |
| Antidepressants | 9 (8%) |
| Clopidogrel/tramadol | 1 (1%) |
| Cardiovascular medications | 2 (2%) |
| Multiple drug classes | 1 (1%) |
| Warfarin | 15 (14%) |
| Cohort Type | |
| Hypothetical | 75 (69%) |
| Observational | 19 (18%) |
| Randomized controlled trial | 7 (6%) |
| Multiple | 7 (6%) |
| Perspective | |
| Patient | 1 (1%) |
| Payer | 32 (30%) |
| Societal | 20 (19%) |
| US healthcare system | 13 (12%) |
| Universal healthcare system | 24 (22%) |
| Multiple | 4 (4%) |
| Not stated | 14 (13%) |
| Funding source | |
| Government | 6 (6%) |
| Grant/foundation | 46 (43%) |
| Pharma | 14 (13%) |
| University/institute | 9 (8%) |
| No funding | 16 (15%) |
| Not stated | 17 (16%) |
| QHES scores | |
| High quality (≥75) | 94 (87%) |
| Not high quality (<75) | 14 (13%) |
CYP, cytochrome P450; DPYD, dihydropyrimidine dehydrogenase; HLA, human leukocyte antigen; IFNL3, interferon lambda 3; mt‐RNR1, mitochondrially encoded 12S ribosomal RNA; Pharma, pharmaceutical industry; SLCO1B1, solute carrier organic anion transporter family member 1B1; TPMT, thiopurine‐S‐methyltransferase; UGT1A1, UDP glucuronosyltransferase family 1 member A1.